Anti-CHIKUNGUNYA IgM

Bacterial/ Viral

Report in 4Hrs

At Home

No Fasting Required

Details

Detects IgM antibodies against Chikungunya virus.

₹1,554₹2,220

30% OFF

Anti-CHIKUNGUNYA IgM - Comprehensive Medical Test Guide

Why is it done?
- Detection of acute Chikungunya virus infection through identification of IgM antibodies produced during the early immune response
- Diagnosis of symptomatic Chikungunya fever in patients presenting with acute febrile illness, severe joint pain (arthralgia), and rash
- Differentiation of Chikungunya from other arboviral diseases such as Dengue fever, Zika virus, and other febrile illnesses
- Epidemiological surveillance and outbreak investigation in endemic and epidemic regions
- Typical timing: Performed during the acute phase of illness (first 5-7 days after symptom onset) when IgM antibodies are most detectable
- Risk assessment in travelers returning from endemic areas (Africa, Asia, Indian subcontinent, Caribbean, Pacific islands)
Normal Range
- Negative/Undetectable: Less than 0.8 IU/mL (or < 1:20 for titer-based testing) or Negative (depending on laboratory methodology)
- Positive: ≥ 0.8 IU/mL or ≥ 1:20 titer or values exceeding the laboratory-specific cutoff
- Units of measurement: IU/mL (International Units per milliliter), Antibody Index (AI), or Titer ratios (1:20, 1:40, 1:80, etc.)
- Normal interpretation: Negative result indicates absence of acute Chikungunya infection; may be negative early in illness (before day 3-5) requiring repeat testing
- Abnormal interpretation: Positive result indicates acute or recent Chikungunya virus infection, particularly if accompanied by clinical symptoms and epidemiological context
- Note: Reference ranges vary by laboratory and testing method (ELISA, immunofluorescence, rapid test); always consult laboratory-specific reference values
Interpretation
- Positive Result:
  - Indicates acute or recent (within 1-3 months) Chikungunya virus infection
  - IgM antibodies are typically present 3-5 days after symptom onset and persist for 1-3 months
  - High titers or strong positivity suggest active or very recent infection
- Negative Result:
  - Indicates absence of acute Chikungunya infection or testing performed too early in disease course (before antibody formation)
  - May represent remote/past infection if tested >3 months after symptom onset
  - Repeat testing may be warranted if clinical suspicion remains high
- Factors Affecting Results:
  - Timing of blood collection: Peak IgM levels occur at 1-3 weeks post-symptom onset
  - Cross-reactivity: May show false positivity with other alphaviruses (Ross River, O'Nyong'nyong) or dengue antibodies
  - Immunocompromised status may affect antibody production and detection
  - Laboratory methodology variations: Different assays (ELISA, IFA, lateral flow) may have different sensitivities and specificities
  - Prior Chikungunya infection may result in very weak or false-negative IgM in reinfection scenarios
- Clinical Significance:
  - Positive IgM in acute phase with compatible symptoms (fever, arthralgia, rash) confirms Chikungunya diagnosis
  - Most useful for diagnosis within first 3 months of illness onset
  - Should be interpreted alongside clinical presentation and epidemiological data for accurate diagnosis
Associated Organs & Conditions
- Primary Organ Systems Involved:
  - Musculoskeletal system: Joints (particularly small joints of hands and feet, knees, ankles, wrists) - most characteristic feature
  - Lymphatic system and immune system: Site of initial viral replication and antibody response
  - Integumentary system (skin): Characteristic rash manifestations
  - Neurological system: Central nervous system complications in severe cases
- Diseases/Conditions Associated with Abnormal Results:
  - Acute Chikungunya fever: Acute febrile illness with high fever, severe polyarthralgia/polyarthritis, rash
  - Chronic arthritis: Post-Chikungunya arthralgia/arthritis lasting months to years
  - Meningitis and encephalitis: CNS involvement in severe cases
  - Hemorrhagic manifestations: Bleeding complications in severe disease
  - Myocarditis: Cardiac inflammation (rare)
- Potential Complications:
  - Chronic polyarthritis: Long-term joint pain and disability affecting quality of life
  - Neurological sequelae: Guillain-Barré syndrome, myelitis, cognitive impairment
  - Severe disease in immunocompromised patients: Prolonged viremia and systemic complications
  - Maternal-fetal transmission: Risk of vertical transmission during pregnancy
Follow-up Tests & Monitoring
- Confirmatory & Complementary Tests:
  - Anti-CHIKUNGUNYA IgG: To confirm past infection or assess for chronic/convalescent phase; persistent after IgM decline
  - Chikungunya RT-PCR: Viral nucleic acid detection; most specific during acute phase (first 5-7 days); confirms active infection
  - Dengue IgM/IgG: To rule out Dengue co-infection or differentiate from Dengue fever (high overlap in endemic regions)
  - Zika virus IgM/RT-PCR: To differentiate from Zika virus infection (similar clinical presentation)
- Additional Diagnostic Tests:
  - Complete Blood Count (CBC): May show leukopenia, lymphocytosis, or thrombocytopenia
  - Liver Function Tests (LFTs): To assess for hepatic involvement; mild elevation of transaminases possible
  - C-Reactive Protein (CRP) and ESR: Inflammatory markers to assess disease severity and progression
  - Cerebrospinal Fluid (CSF) analysis: If meningitis/encephalitis suspected with neurological symptoms
- Monitoring & Follow-up Frequency:
  - Acute phase: Repeat IgM testing 5-7 days later if initial test is negative but clinical suspicion remains high
  - Chronic phase: IgG testing at 2-4 weeks to confirm seroconversion and assess for persistent infection
  - Persistent arthralgia: Follow-up clinical assessment at 1, 3, and 6 months; imaging studies (X-ray, ultrasound) if severe
  - Severe/complicated cases: More frequent monitoring including imaging, specialist consultation, and repeat serologies
- Related Tests Providing Complementary Information:
  - Viral culture and antigen detection: Specialized testing in reference laboratories
  - Serological panel for other arboviruses: Multiplex testing for dengue, Zika, West Nile virus
  - Rheumatological workup: If chronic arthritis develops (RF, ANA, complement levels)
Fasting Required?
- No, fasting is NOT required
- Duration: N/A - No fasting restrictions apply to this serum antibody test
- Medications: No specific medications need to be avoided; continue all regular medications as prescribed
- Note: Immunosuppressive medications (corticosteroids, immunosuppressants) may theoretically reduce antibody response but should not be discontinued without physician guidance
- Patient Preparation Requirements:
  - Routine venipuncture only; no special physical preparation needed
  - Timing: Optimal timing is 3-5 days after symptom onset for maximum IgM detection; repeat testing at 5-7 days if initial test negative
  - Sample collection: Serum from venipuncture or whole blood collection into appropriate separator tube
  - Hydration status: No specific hydration restrictions; patient may drink water
  - Stress/exercise: No specific restrictions; normal daily activities acceptable

How our test process works!